市場調査レポート

エピゲノミクス:医薬品・診断の現在・将来のアプリケーション

Epigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation, Histone Modification and miRNA expression)

発行 Kalorama Information 商品コード 248850
出版日 ページ情報 英文 160 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
エピゲノミクス:医薬品・診断の現在・将来のアプリケーション Epigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation, Histone Modification and miRNA expression)
出版日: 2012年08月10日 ページ情報: 英文 160 Pages
概要

当レポートでは、エピゲノミクスの基礎科学と民間企業によって報告された実績について検討しており、市場における主要企業の活動、研究者および民間企業のリーダーへのインタビュー、現在のエピジェノミック医薬品推計と予測、エピゲノミクスの影響を受ける主な医療セグメント、現在承認されているエピゲノミック医薬品、医薬品のR&D、アルツハイマー病など各疾病におけるアプリケーションの分析などについてまとめ、概略下記の構成で取り上げております。

第1章 エグゼクティブサマリー

第2章 エピジェネティクスの基礎科学

  • 健康と疾病の新しい見方
  • 現在までのエピジェネティクスの歴史
  • 調査範囲
  • エピジェネティクスとは何か?
  • 挑戦の新しいレベル
  • 医療産業の予測
  • 大観図:Dr. Michael Skinner へのインタビュー
  • エピジェネティック制御機構の分子生物学
  • ヒストンのアセチル化とその他の変更点
  • サマリー、結論

第3章 エピジェネティックと診断

  • 疾病のエピジェネティック促進因子
  • ヒストンの役割
  • 初期癌の診断
  • メチル化市場
  • サマリー、結論

第4章 市場促進因子

  • エピジェネティクスおよび治療:市場、主要疾病別
  • 抗癌治療
  • 精神疾患
  • 脆弱性X症候群
  • フリードライヒ失調症
  • 注意書についての結論

第5章 エピジェネティクスの市場参入企業

  • 診断企業
  • Enzo Life Sciences
  • Epigenomics AG
  • Exact Sciences
  • 治療企業
  • エピジェネティクス研究製品供給企業
  • サマリー、結論

第6章 エピジェネティクス市場の見通し

  • 世界市場における成長:全体
  • 製薬企業の前途は暗い:逆転する方法
  • 機会:エピジェネティックをベースにした癌治療の巨大な市場
  • IVD市場
  • 全体的なIVD市場
  • 特定のエピジェネティックIVD市場分析
  • 個別医療とエピジェネティクス
  • 産業課題・戦略的提案
  • 競合情勢
  • エピジェネティクス市場全体
  • 市場促進因子・阻害因子
  • 市場予測・競合分析
  • 世界のエピジェネティック市場
  • 見通し
  • サマリー、結論

図表

目次
Product Code: KLI7087795

Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenomics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.

Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.

Epigenomic Mechanisms Discussed in the report include:

  • DNA methylation
  • Histone Acetylation
  • Histone Phosphorylation
  • Methylation
  • Sumoylation
  • Histone “chaperones”
  • MicroRNAs (miRNAs)

The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies.

In doing so, the report provides:

  • Discussion of the Basic Science and Mechanisms Behind Epigenomics
  • Activities of Top Companies in the Market
  • Interviews with Researchers and Private Sector Leaders
  • Market Estimates for Current Epigenomic Drugs and Forecast to 2017
  • Market Estimates for Current Epigenomic Diagnostics and Comparison to Next Gen Cancer Diagnostics Market
  • Analyst Conclusions Regarding the Future Market for Epigenomics
  • Key Healthcare Segments Impacted by Epigenomics
  • Examples of Clinically Relevant Epigenetic Biomarkers
  • Currently Approved Epigenomic Drugs
  • Epigenetic Drivers of Disease
  • Pharmaceutical R&D: A Need for Better Returns
  • Look at Applications in Alzheimer's Disease, Mental Illness, Auto-Immune Diseases, Autism and Cardiovascular Disease

The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market. As the report states:

"In the examination of Google hits for “Epigenomics,” the phrases “exciting”, “state of the art”, “cutting edge”, “innovative”, “breakthrough” and other cliches are encountered over and over. These terms are frequently employed to cover up ideas, concepts and scientific discoveries that may NOT be cutting edge or state of the art and may be past their time, or may never have reached their time. For this reason the report will consider which of these technologies have value and may be ripe for exploitation."

The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • The Basic Science of Epigenetics- Basic Life Science R&D
  • Epigenetics and Diagnostics
  • Outlook for epigenetics R&D

CHAPTER TWO: THE BASIC SCIENCE OF EPIGENETICS

  • A New Look at Health and Disease.
    • Lamarck
    • Weissmann
  • The History of Epigenetics to the Present
  • What This Report Covers
  • What is Epigenetics?
    • The concept.
  • A New Level of Challenge
  • Implications for the Healthcare industry
  • The Big Picture: An interview with Dr. Michael Skinner
  • The Molecular Biology of Epigenetic Control Mechanisms
    • DNA methylation
  • Histone acetylation and other modifications
    • Complex; not well understood
    • Histone Acetylation
    • Histone phosphorylation
    • Methylation
    • Sumoylation
    • Histone “chaperones”
    • MicroRNAs (miRNAs)
  • Summary, Conclusions

CHAPTER THREE: EPIGENETIC AND DIAGNOSIS

  • Epigenetic drivers of disease
    • Epigenetics and DNA methylation
  • Role of histones
  • Early cancer diagnosis
  • Methylation Markers
    • Challenges in the Identification of Epigenetic Involvement in Non-Cancerous Diseases
  • Summary, Conclusions

CHAPTER FOUR: MARKET DRIVERS

  • Epigenetics and Therapeutics: Market by major diseases
  • Cancers
    • Hypo/Hypermethylation
  • Anti-Cancer Therapy
    • Covalent histone modifications
    • Aberrant miRNA expression
    • Autoimmune dysfunction
    • Cardiovascular
  • Mental Disorders
    • A classic Vision of Mental Illness
    • Schizophrenia
    • Bipolar disorder
    • Autism
    • Alzheimer's Disease
    • Spinal muscular Atrophy (SMA)
    • Parkinson's Disease
    • Imprinting Disorders
    • Praeder-Willi Syndrome
    • Angelman Syndrome
    • Beckwith-Wiedemann Syndrome
  • Fragile X Syndrome
  • Friedreich's Ataxia
  • Concluding on a Cautionary Note

CHAPTER FIVE: COMPANIES ACTIVE IN EPIGENOMICS

  • Diagnostic companies
  • Enzo Life Sciences
  • Epigenomics AG
    • Epiontis
  • Exact Sciences
    • Illumina
    • Novus Biologicals
    • Oncomethylome Sciences
    • Valirx
    • Volition Singapore
  • Therapeutic Companies
    • Acetylon Pharmaceuticals
    • Acylin Therapeutics
    • CellCentric
    • Celdex
    • Celgene
    • Celzome (UK/DE)
    • Chroma Therapeutics
    • Constellation Pharma
    • Eisai Co. Ltd
    • Epitherapeutics
    • EpiZyme
    • Methyl Gene
    • Novartis:
    • Orion
    • RaNA Therapeutics
    • Syndax Pharmaceuticals Inc.
    • ValiRX (UK)
  • Epigenetics research products supply companies
    • Active Motif
    • Diagenode
    • Epigentek
    • Life Technologies
    • Qiagen
    • Sigma-Aldrich
    • Zymo Research Products
  • Summary, Conclusions

CHAPTER SIX: OUTLOOK FOR THE EPIGENETICS MARKET

  • Growth in World Markets; Overall
  • Dim Prospects for Pharma: How to Upend them
  • Upsides, Opportunities: A huge market for epigenetic-based cancer treatments.
  • The IVD market
  • The Overall IVD Market
  • Specific Epigenetic IVD market breakdown
  • Personalized medicine and epigenetics
  • Industry Challenges and Strategic Recommendations
  • Competitive landscape
  • Total Epigenetics Market 2008-2017
  • Market Drivers and Restraints
  • Market Forecasts and Competitive Analysis
    • Revenue Forecasts
    • Competitive Structure
    • Competitive Metrics
    • Market Share Analysis: Product segments
  • WW Epigenetic Market 2008-2017
    • North America
    • EU
    • Japan
    • Asia Pacific
    • Ominous signs from China
  • The Way Forward
    • South America
  • Summary, Conclusions

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1:The most common epigenetic alterations

CHAPTER TWO: THE BASIC SCIENCE OF EPIGENETICS

  • Figure 2-1 Timeline of epigenetic discoveries ourtesy Constellation Pharma
  • Table 2-1 The most common epigenetic alterations
  • Figure 2-2 Agouti Mice
  • Figure 2-3 Classic DNA methylation reaction
  • Figure 2-4 The molecule 5-hydroxymethylcytosine
  • Figure 2-5 DNA molecule wrapped twice around a Hisotne Octamer to make a Nucleosome
  • Table 2-2 Varieties of histone modification and their properties
  • Figure 2-6 Acetylation and deacetylation of lysene residues
  • Figure 2-7 Shilatifard A. 2008

CHAPTER THREE: EPIGENETIC AND DIAGNOSIS

  • Table 3-1: Examples of Clinically Relevant Epigenetic Biomarkers

CHAPTER FOUR: MARKET DRIVERS

  • Table 4-1: Currently FDA-approved Epigenetic-Based Drugs
  • Figure 4-1: Structures of (A) 5-aza 2'-deoxycytidine (5 aza - dC, decitabine) and (B) zebularine
  • Figure 4-2: U.S. FDA-approved Epigenetic-Acting Drugs
  • Table 4-3: Prevalance of Autism as a Function Time, 200-2008
  • Table 4-4: Current Autism Therapies
  • Figure 4-3: Map of the 11p15 imprinted region

CHAPTER FIVE: COMPANIES ACTIVE IN EPIGENOMICS

  • Table 5-1: Some Important Epigenetics Diagnostics Companies
  • Table 5-2: The Epigenetics Land Grab: R&D from Major Pharma Companies
  • Figure 5-2: JUN/EPIZYME An Example of one of Epizyme's inhibitors interacting with an epigenetic enzyme
  • Figure 5-3: Structure of LBH589 (panobinostat)
  • Figure 5-4: Action of Panbinostat
  • Figure 5-5: Structure of Entinostat

CHAPTER SIX: OUTLOOK FOR THE EPIGENOMICS MARKET

  • Table 6.1:GNP Growth by Country, Region
  • Table 6.2: Conflicting Worldwide Economic Drivers And Their Impact On Epigenomics Technologies
  • Figure 6.1: Vast Expenditures, Poor Returns
  • Table 6.3: Guidelines For A New Stage Of Drug Development
  • Table 6.4: Epigenomics Therapeutics Market, 2011 and 2017 (millions)
  • Table 6.5: Global Pharma Market, 2010 and 2015 (billions)
  • Figure 6.2: Epigenomic Drug Market, 2011 and 2017
  • Table 6.6: FDA-Approved Epigenetic Anti-Cancer Agents
  • Figure 6.3: Epigenomics Diagnostics Market, 2010 and 2015
  • Table 6.7: Next Gen Cancer Diagnostics Market, 2010-2015
  • Table 6.8: Epigenomics in Cancer Diagnostics, 2010-2015
  • Table 6.9: Total IVD Market 2007-2011
  • Table 6.10: Some Current Epigenomics Research Goals
  • Table 6.11: Cancer Diagnostics Market
  • Table 6.12: Some Major Companies And Their Activities
  • Figure 6.4: Publications on Epigenomics and Cardiovascular Disease
  • Table 6.13: Takeda regional Portfolio Blance As a Bellweather
Back to Top